CompanyDrug

Nanjing Zenshine’s ZX-7101A NDA Accepted by NMPA for Uncomplicated Influenza Treatment

Company

Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Company

Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle

Company

Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales

Policy / Regulatory

Medical Institutions Directed to Adhere to ‘Six Should Do’s’ and ‘Six Prohibited Behaviors’ for Academic Lectures

Policy / Regulatory

China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development

Company

Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024

CompanyDrug

Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss

Company

Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales

CompanyDrug

Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag

CompanyDrug

BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers